期刊
JOURNAL OF NUCLEAR MEDICINE
卷 50, 期 1, 页码 88-99出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.054205
关键词
F-18-FDG; PET; PET/CT; tumor response; treatment monitoring; outcome
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With F-18-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with F-18-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据